Chilean Interventional Open Label Pilot Study, to Assess the Efficacy and Safety of Lucentis (Ranibizumab Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema.
Phase of Trial: Phase IV
Latest Information Update: 22 Feb 2019
Price : $35 *
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 02 May 2017 Status changed from active, no longer recruiting to completed.
- 30 Jun 2016 Planned End Date changed from 1 Apr 2015 to 1 Jan 2017.
- 30 Jun 2016 Planned primary completion date changed from 1 Apr 2015 to 1 Jan 2017.